Oncternal TherapeuticsONCT
13F holders, Q4 2024 (December 31)4holders −19
0new positions
21sold out
$0.01avg. 13F price*
At the end of Q4 2024, 4 institutions reported holding Oncternal Therapeutics Inc. (ONCT) in their 13F filings, down 19 from Q3 2024. 0 opened new positions and 21 sold out. The largest holders were Steward Partners Investment Advisory, LLC ($8), Nemes Rush Group LLC ($2) and Acadian Asset Management LLC ($0).
- Company
- Oncternal Therapeutics Inc.
- CUSIP
- 68236P206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 21 | $469K |
All 13F filers, Q3 2024 → Q4 2024: 355,398 shares sold, net −355,398 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 15 | $8 |
| Nemes Rush Group LLC | 0.00% | No change | 3 | $2 |
| Acadian Asset Management LLC | 0.00% | No change | 1,829 | $0 |
| Parvin Asset Management, LLC | 0.00% | — | 40 | $0 |
"% of holder's portfolio" is ONCT's weight in each manager's 13F, not the share of Oncternal Therapeutics Inc. the manager owns.